Tokyo Tape
Sign in
← Takeda Pharmaceutical

Annual report

4502.TEDINET S100YB5L
Period2025-04-01 → 2026-03-31
Filed2026-06-17
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥4.51T2025-04-01 → 2026-03-31Cons.Revenue IFRS
Revenue¥4.58T2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥4.26T2023-04-01 → 2024-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥4.03T2022-04-01 → 2023-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥3.57T2021-04-01 → 2022-03-31vCons.Revenue IFRS (5-year summary)
Operating income¥6.2bn2025-04-01 → 2026-03-31Cons.Operating profit loss IFRS
Operating income¥342.6bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Profit before tax−¥142.4bn2025-04-01 → 2026-03-31Cons.Profit loss before tax IFRS
Profit before tax¥175.1bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥52.8bn2023-04-01 → 2024-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥375.1bn2022-04-01 → 2023-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥302.6bn2021-04-01 → 2022-03-31vCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)−¥152.4bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥107.9bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥144.1bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥317.0bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥230.1bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income−¥152.1bn2025-04-01 → 2026-03-31Cons.Profit loss IFRS
Net income¥108.1bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Net income¥144.2bn2023-04-01 → 2024-03-31vCons.Profit loss IFRS (5-year summary)
Net income¥317.0bn2022-04-01 → 2023-03-31vCons.Profit loss IFRS (5-year summary)
Net income¥230.2bn2021-04-01 → 2022-03-31vCons.Profit loss IFRS (5-year summary)
Total assets¥15.51Tat 2026-03-31Cons.Assets IFRS
Total assets¥14.25Tat 2025-03-31Cons.Assets IFRS
Total assets¥15.11Tat 2024-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥13.96Tat 2023-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥13.18Tat 2022-03-31vCons.Total assets IFRS (5-year summary)
Total liabilities¥8.08Tat 2026-03-31Cons.Liabilities IFRS
Total liabilities¥7.31Tat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥7.43Tat 2026-03-31Cons.Equity IFRS
Net assets / equity¥6.94Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥7.27Tat 2024-03-31vCons.Equity IFRS
Equity (owners)¥7.43Tat 2026-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥6.94Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Cash & equivalents¥595.1bnat 2026-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥385.1bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥457.8bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Cash & equivalents¥533.5bnat 2023-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥849.7bnat 2022-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥1.04T2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥1.06T2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥716.3bn2023-04-01 → 2024-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥977.2bn2022-04-01 → 2023-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.12T2021-04-01 → 2022-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥369.1bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥367.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥463.9bn2023-04-01 → 2024-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥607.1bn2022-04-01 → 2023-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥198.1bn2021-04-01 → 2022-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥496.8bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥751.4bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥354.4bn2023-04-01 → 2024-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥709.1bn2022-04-01 → 2023-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.07T2021-04-01 → 2022-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥-96.752025-04-01 → 2026-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥68.362024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥92.092023-04-01 → 2024-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥204.292022-04-01 → 2023-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥147.142021-04-01 → 2022-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-96.752025-04-01 → 2026-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.232024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥91.162023-04-01 → 2024-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥201.942022-04-01 → 2023-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥145.872021-04-01 → 2022-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥4,702.66at 2026-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,407.01at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,635.56at 2024-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,087.49at 2023-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,665.61at 2022-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio47.9%at 2026-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio48.7%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio48.1%at 2024-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio45.5%at 2023-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.1%at 2022-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE-2.1%2025-04-01 → 2026-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE1.5%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE2.1%2023-04-01 → 2024-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE5.3%2022-04-01 → 2023-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE4.2%2021-04-01 → 2022-03-31vCons.Rate of return on equity IFRS (5-year summary)
Employees47,029at 2026-03-31Cons.Number of employees
Employees47,455at 2025-03-31Cons.Number of employees
Employees49,281at 2024-03-31vCons.Number of employees
Employees49,095at 2023-03-31vCons.Number of employees
Employees47,347at 2022-03-31vCons.Number of employees
Revenue¥591.6bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥580.4bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥595.6bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥632.1bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥764.3bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥21.1bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥36.9bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥205.5bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥86.6bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥286.4bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥340.1bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥550.9bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥187.0bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥199.3bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥197.3bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥152.8bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥338.9bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥330.6bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥324.4bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥9.64Tat 2026-03-31StandaloneAssets
Total assets¥9.49Tat 2025-03-31StandaloneAssets
Total assets¥9.76Tat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥9.41Tat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥9.64Tat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥5.88Tat 2026-03-31StandaloneLiabilities
Total liabilities¥5.50Tat 2025-03-31StandaloneLiabilities
Net assets / equity¥3.76Tat 2026-03-31StandaloneNet assets
Net assets / equity¥3.99Tat 2025-03-31StandaloneNet assets
Net assets / equity¥4.09Tat 2024-03-31vStandaloneNet assets
Net assets / equity¥4.21Tat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥4.29Tat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥73.9bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥169.6bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥125.292025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥96.792024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥216.62023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥213.062022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥207.52021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥125.262025-04-01 → 2026-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥96.782024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥216.562023-04-01 → 2024-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥213.052022-04-01 → 2023-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥207.52021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥2002025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1962024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1882023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,378.68at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,534.39at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,604.87at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥2,704.87at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥2,769.31at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio39.0%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio42.0%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio41.9%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio44.7%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio44.5%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE5.1%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE3.8%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE8.2%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE7.8%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE7.4%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued1,591,229,000at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,590,950,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,419,000at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,296,000at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,253,000at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees4,792at 2026-03-31StandaloneNumber of employees
Employees4,808at 2025-03-31StandaloneNumber of employees
Employees5,474at 2024-03-31vStandaloneNumber of employees
Employees5,486at 2023-03-31vStandaloneNumber of employees
Employees5,149at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2026-03-3147029 pure
Pharmaceutical Businessreportable segmentemployeesat 2026-03-314792 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,774
ItemContextValueUnit
Net assetsCurrentYearInstant_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-691253000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember-683092000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember994000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember3758926000000JPY
Sales commission sgaPrior1YearDuration_NonConsolidatedMember33872000000JPY
Sales commission sgaCurrentYearDuration_NonConsolidatedMember34562000000JPY
Salaries sgaPrior1YearDuration_NonConsolidatedMember28701000000JPY
Salaries sgaCurrentYearDuration_NonConsolidatedMember23650000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember8196000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember6272000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember7921000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember7202000000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember11675000000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember19818000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember152006000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember142942000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-06-17
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第149期(自　2025年４月１日　至　2026年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)武田薬品工業株式会社
Company name in english cover pageFilingDateInstantTakeda Pharmaceutical Company Limited
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO　　クリストフ ウェバー
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市中央区道修町四丁目１番１号（上記は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目１番１号(武田薬品工業株式会社武田グローバル本社)
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03(3278)2111(代表)
Name of contact person nearest place of contact cover pageFilingDateInstantText · Plus
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00919
Fund codeFilingDateInstant－
Security codeFilingDateInstant45020
Filer name in japaneseFilingDateInstant
Original text (Japanese)武田薬品工業株式会社
Filer name in englishFilingDateInstantTakeda Pharmaceutical Company Limited
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2025-04-01
Current period end dateFilingDateInstant2026-03-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2026-03-31
Previous fiscal year start dateFilingDateInstant2024-04-01
Comparative period end dateFilingDateInstant2025-03-31

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2026-03-31pass rounding
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass